Clinical Trials · NCT02788578

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

Phase
N/A
Recruitment status
Terminated
Sponsor
Ipsen
Enrollment
40
Start date
Jun 2016
Locations
12 sites, 5 countries
Primary endpoint
Progression Free Survival (PFS) rate according to the central reading using RECIST (Version 1.1)
View Lanreotide compound reference